| HOME >> BIOLOGY >> TECHNOLOGY |
• Provides patent analysis with respect to competitors and geography.
Scope of this report• • Understand and evaluate the growth potential of emerging technologies.
• Understand biomarker activity in clinical trials of leading market players.
• Gain knowledge about the relative importance of the biomarker late stage clinical trials technologies in the next five years for investment opportunities.
• Learn which therapy areas leading market players in the late stage biomarker clinical trials market.
• Determine the collaborations and partnerships of the major market players.
Key Market Issues• The pharmaceutical and biotech sectors are currently facing increasing duration and cost issues related to clinical trials in drug discovery.
• Funding from government sources such as the National Institutes of Health (NIH) has not increased significantly over the last few years.
• Late stage failures are much more expensive than early ones.
• The rising demand for better safety data has put a considerable amount of regulatory and economic pressure on pharmaceutical companies.
• The current average approval rate of cancer drugs is as low as 5%, while the development period can reach 15 years.
• More than 50% of clinical trials fail in Phase III due to a host of reasons, greater disease complexity, stiffer clinical endpoints, and the inability of the data to prove drug effectiveness.
Key findings from this report• The biomarkers in late stage clinical trials market is largest in North American and European region, with Europe having the second largest market.
• North America constitutes the major market share with the immunoassay, flow cytometry and GC/MS and LC/MS having high market growth.
• Caprion p
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |